These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12204667)

  • 1. Tamoxifen beyond 5 years--patients' decisions regarding entry to the aTTom trial.
    Ferguson MJ; Dewar JA
    Eur J Cancer; 2002 Sep; 38(14):1857-9. PubMed ID: 12204667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The optimal duration of adjuvant tamoxifen treatment for breast cancer remains uncertain: randomize into aTTom.
    Earl H; Gray R; Kerr D; Lee M
    Clin Oncol (R Coll Radiol); 1997; 9(3):141-3. PubMed ID: 9269542
    [No Abstract]   [Full Text] [Related]  

  • 3. Adjuvant treatment with tamoxifen. Informed consent and follow up in aTTom trial are inadequate.
    Cunningham H
    BMJ; 1996 Aug; 313(7055):494. PubMed ID: 8776338
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group.
    Stewart HJ; Forrest AP; Everington D; McDonald CC; Dewar JA; Hawkins RA; Prescott RJ; George WD
    Br J Cancer; 1996 Jul; 74(2):297-9. PubMed ID: 8688340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.
    Derks MGM; Blok EJ; Seynaeve C; Nortier JWR; Kranenbarg EM; Liefers GJ; Putter H; Kroep JR; Rea D; Hasenburg A; Markopoulos C; Paridaens R; Smeets JBE; Dirix LY; van de Velde CJH
    Lancet Oncol; 2017 Sep; 18(9):1211-1220. PubMed ID: 28732650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
    Tjan-Heijnen VCG; van Hellemond IEG; Peer PGM; Swinkels ACP; Smorenburg CH; van der Sangen MJC; Kroep JR; De Graaf H; Honkoop AH; Erdkamp FLG; van den Berkmortel FWPJ; de Boer M; de Roos WK; Linn SC; Imholz ALT; Seynaeve CM;
    Lancet Oncol; 2017 Nov; 18(11):1502-1511. PubMed ID: 29031778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of adjuvant tamoxifen therapy.
    Bryant J; Fisher B; Dignam J
    J Natl Cancer Inst Monogr; 2001; (30):56-61. PubMed ID: 11773293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adjuvant tamoxifen duration: more large-scale randomized evidence is needed].
    Davies C; Nomura Y; Ohashi Y
    Gan To Kagaku Ryoho; 1997 Aug; 24(10):1203-9. PubMed ID: 9279337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years.
    Stewart HJ; Prescott RJ; Forrest AP
    J Natl Cancer Inst; 2001 Mar; 93(6):456-62. PubMed ID: 11259471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen for early breast cancer.
    Early Breast Cancer Trialists' Collaborative Group
    Cochrane Database Syst Rev; 2001; (1):CD000486. PubMed ID: 11279694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors implicated in the decision whether or not to join the tamoxifen trial in women at high familial risk of breast cancer.
    Lovegrove E; Rumsey N; Harcourt D; Cawthorn SJ
    Psychooncology; 2000; 9(3):193-202. PubMed ID: 10871715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
    Mathew A; Davidson NE
    Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast surgery in the 'Arimidex, Tamoxifen Alone or in Combination' (ATAC) trial: American women are more likely than women from the United Kingdom to undergo mastectomy.
    Locker GY; Sainsbury JR; Cuzick J;
    Cancer; 2004 Aug; 101(4):735-40. PubMed ID: 15305403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.
    Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Cuzick J; Coibion M; Bianco AR
    BJOG; 2003 Dec; 110(12):1099-106. PubMed ID: 14664881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights into endocrine therapy for young women with breast cancer.
    Di Lascio S; Pagani O
    Womens Health (Lond); 2015 Jun; 11(3):343-54. PubMed ID: 26102472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twelve-year mortality results of a randomized trial of 2 versus 5 years of adjuvant tamoxifen for postmenopausal early-stage breast carcinoma patients (SITAM 01).
    Belfiglio M; Valentini M; Pellegrini F; De Berardis G; Franciosi M; Rossi MC; Sacco M; Nicolucci A;
    Cancer; 2005 Dec; 104(11):2334-9. PubMed ID: 16245354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women.
    Demissie S; Silliman RA; Lash TL
    J Clin Oncol; 2001 Jan; 19(2):322-8. PubMed ID: 11208822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.